Introduction to depot buprenorphine in the treatment of opioid dependent patients

Webinar summary

16 October 2019

Long acting depot buprenorphine was listed on the Pharmaceutical Benefits Scheme (PBS) on the 1st September 2019 as an s100 drug, making it free to people with an opioid dependency. This webinar explains the clinical guidance, evidence base, pharmacology, and risks associated with depot buprenorphine, and how to implement it as an Opioid Agonist Treatment (OAT) for opioid dependency.

We discuss skills to help you identify suitable patients for depot buprenorphine and have conversations about the risks and benefits, and how to comply with the regulatory requirements of prescribing and storing of depot buprenorphine.


Professor Nicholas Lintzeris

Dr Hester Wilson